Lopez Mary F, Mikulskis Alvydas, Kuzdzal Scott, Bennett David A, Kelly Jeremiah, Golenko Eva, DiCesare Joseph, Denoyer Eric, Patton Wayne F, Ediger Richard, Sapp Lisa, Ziegert Tillmann, Lynch Christopher, Kramer Susan, Whiteley Gordon R, Wall Michael R, Mannion David P, Della Cioppa Guy, Rakitan John S, Wolfe Gershon M
PerkinElmer Life and Analytical Sciences, Boston, MA 02118, USA.
Clin Chem. 2005 Oct;51(10):1946-54. doi: 10.1373/clinchem.2005.053090. Epub 2005 Aug 4.
Researchers typically search for disease markers using a "targeted" approach in which a hypothesis about the disease mechanism is tested and experimental results either confirm or disprove the involvement of a particular gene or protein in the disease. Recently, there has been interest in developing disease diagnostics based on unbiased quantification of differences in global patterns of protein and peptide masses, typically in blood from individuals with and without disease. We combined a suite of methods and technologies, including novel sample preparation based on carrier-protein capture and biomarker enrichment, high-resolution mass spectrometry, a unique cohort of well-characterized persons with and without Alzheimer disease (AD), and powerful bioinformatic analysis, that add statistical and procedural robustness to biomarker discovery from blood.
Carrier-protein-bound peptides were isolated from serum samples by affinity chromatography, and peptide mass spectra were acquired by a matrix-assisted laser desorption/ionization (MALDI) orthogonal time-of-flight (O-TOF) mass spectrometer capable of collecting data over a broad mass range (100 to >300,000 Da) in a single acquisition. Discriminatory analysis of mass spectra was used to process and analyze the raw mass spectral data.
Coupled with the biomarker enrichment protocol, the high-resolution MALDI O-TOF mass spectra provided informative, reproducible peptide signatures. The raw mass spectra were analyzed and used to build discriminant disease models that were challenged with blinded samples for classification.
Carrier-protein enrichment of disease biomarkers coupled with high-resolution mass spectrometry and discriminant pattern analysis is a powerful technology for diagnostics and population screening. The mass fingerprint model successfully classified blinded AD patient and control samples with high sensitivity and specificity.
研究人员通常采用“靶向”方法寻找疾病标志物,即对疾病机制提出假设,并通过实验结果来证实或否定特定基因或蛋白质与疾病的关联。最近,人们开始关注基于对蛋白质和肽质量的整体模式差异进行无偏量化来开发疾病诊断方法,通常是对患有和未患疾病个体的血液进行分析。我们结合了一系列方法和技术,包括基于载体蛋白捕获和生物标志物富集的新型样品制备方法、高分辨率质谱、一组特征明确的患有和未患阿尔茨海默病(AD)的独特队列,以及强大的生物信息学分析,这些为从血液中发现生物标志物增加了统计和程序上的稳健性。
通过亲和色谱从血清样品中分离出与载体蛋白结合的肽,并使用能够在单次采集过程中在较宽质量范围(100至>300,000 Da)内收集数据的基质辅助激光解吸/电离(MALDI)正交飞行时间(O-TOF)质谱仪获取肽质谱图。利用质谱的判别分析来处理和分析原始质谱数据。
结合生物标志物富集方案,高分辨率MALDI O-TOF质谱提供了丰富、可重复的肽特征图谱。对原始质谱进行分析,并用于构建判别疾病模型,然后用盲法样本进行分类验证。
疾病生物标志物的载体蛋白富集结合高分辨率质谱和判别模式分析是一种用于诊断和人群筛查的强大技术。质量指纹模型成功地以高灵敏度和特异性对盲法AD患者和对照样本进行了分类。